Respiratory Conditions We Study
Advanced clinical trial opportunities featuring 2025's most promising breakthrough therapies for challenging respiratory conditions
Pioneering Treatment Advances Through Clinical Research
At Lung Research Florida, we specialize in conducting clinical trials for the most challenging respiratory conditions using cutting-edge approaches that represent the future of pulmonary medicine. Our research focuses on achieving clinical remission and long-term disease modification rather than just symptom management.
Targeted Biologic Therapies
Next-generation treatments targeting specific inflammatory pathways
Precision Medicine
Biomarker-driven treatment selection for optimal outcomes
Novel Mechanisms
First-in-class compounds with revolutionary approaches
Disease Modification
Treatments aimed at achieving clinical remission
Severe Asthma Clinical Trials
Revolutionary biologic therapies targeting multiple inflammatory pathways
Latest Breakthrough Research (2025)
We're investigating the most advanced biologic treatments available, including next-generation dual-pathway inhibitors and novel inhaled small molecule therapies that represent the future of severe asthma management.
Anti-TSLP Monoclonal Antibodies
Revolutionary upstream targeting of thymic stromal lymphopoietin for patients with both eosinophilic and non-eosinophilic severe asthma. These treatments work regardless of baseline inflammatory markers.
Dual-Pathway Biologic Inhibitors
Next-generation compounds targeting both IL-4/IL-13 and IL-5 pathways simultaneously for superior clinical outcomes and potential disease remission.
Inhaled JAK1 Selective Inhibitors
Novel small molecule therapies delivered directly to the lungs, offering targeted anti-inflammatory effects with reduced systemic exposure.
Ultra-Long-Acting Anti-IL-5 Therapy
Innovative twice-yearly biologic injections for eosinophilic asthma, dramatically improving convenience and adherence.
What Makes Our Asthma Trials Unique
- Biomarker-Driven Selection: Advanced testing to match you with the most effective treatment
- Clinical Remission Focus: Aim for complete symptom control, not just improvement
- Comprehensive Monitoring: Regular lung function testing, inflammatory marker assessment, and quality of life evaluations
- Latest 2025 Advances: Access to treatments 3-5 years before public availability
- Personalized Approach: Treatment selection based on your specific asthma phenotype
Who May Qualify for Asthma Trials
Primary Requirements
- Diagnosed with severe asthma by a pulmonologist
- Currently on high-dose inhaled medications
- Two or more severe exacerbations in the past year
- Ages 12-80 years (varies by study)
Advanced Biomarker Criteria
- Elevated blood eosinophils (≥150-300 cells/μL)
- High fractional exhaled nitric oxide (FeNO ≥25 ppb)
- Specific IgE sensitization patterns
- Failed previous biologic therapy (for some studies)
COPD Research & Clinical Trials
Groundbreaking anti-inflammatory approaches and cardiovascular protection
Revolutionary COPD Treatment Advances (2025)
Our COPD research program focuses on preventing exacerbations and protecting cardiovascular health through novel anti-inflammatory biologics and breakthrough disease-modifying approaches that target the root causes of COPD progression.
Anti-IL-33 Biologic Therapy
First-in-class treatments targeting the IL-33 inflammatory pathway, shown to reduce exacerbations and slow disease progression in moderate to severe COPD patients.
Cardiopulmonary Protection Studies
Investigating how optimized COPD treatment can reduce cardiovascular events, addressing the leading cause of death in COPD patients.
IRAK4 Inhibitor Therapy
Novel oral medications targeting innate immune pathways to reduce inflammatory responses and prevent COPD exacerbations.
Precision Phenotyping Trials
Advanced studies using biomarkers to identify COPD subtypes and match patients with the most effective targeted therapies.
Why Participate in Our COPD Trials
- Exacerbation Prevention: Advanced therapies designed to prevent hospitalizations
- Cardiovascular Monitoring: Comprehensive heart health assessment and protection
- Disease Modification: Treatments aimed at slowing COPD progression
- Quality of Life Focus: Improving daily function and exercise capacity
- Latest Technology: Access to cutting-edge COPD monitoring devices
COPD Trial Eligibility
Clinical Requirements
- Confirmed COPD diagnosis with spirometry
- FEV1 between 30-80% predicted
- History of exacerbations requiring treatment
- Ages 40-85 years
Advanced Criteria
- Elevated inflammatory markers (CRP, fibrinogen)
- Cardiovascular risk factors
- Specific emphysema or chronic bronchitis patterns
- Previous exacerbation history
Chronic Cough Clinical Trials
Breakthrough P2X3 receptor antagonists for refractory cough
Revolutionary Chronic Cough Treatments (2025)
We're investigating the most promising treatments for chronic cough, including next-generation P2X3 receptor antagonists with improved side effect profiles and novel neurogenic pathway modulators that address the root causes of persistent cough.
Next-Generation P2X3 Antagonists
Advanced compounds targeting cough-sensing nerves with significantly reduced taste disturbance compared to first-generation medications.
Taste-Neutral Formulations
Innovative drug delivery systems designed to minimize taste side effects while maintaining therapeutic efficacy for chronic cough.
Neurogenic Pathway Modulators
Novel approaches targeting multiple nerve pathways involved in cough hypersensitivity syndrome for comprehensive symptom relief.
Combination Therapy Studies
Research investigating optimal combinations of cough suppressants with anti-inflammatory agents for maximum effectiveness.
Benefits of Our Chronic Cough Trials
- Latest Advances: Access to next-generation P2X3 antagonists with fewer side effects
- Quality of Life Focus: Comprehensive assessment of sleep, social, and emotional impacts
- Cough Monitoring: Objective 24-hour cough counting using advanced digital devices
- Holistic Approach: Addressing both physical symptoms and psychological impacts
- Safety Monitoring: Careful assessment of taste function and other potential effects
Chronic Cough Trial Eligibility
Primary Requirements
- Chronic cough for at least 1 year
- Cough severity score ≥40mm on visual analog scale
- Failed standard treatment approaches
- Ages 18-80 years
Clinical Characteristics
- Unexplained chronic cough or refractory cough
- Normal chest X-ray and lung function
- No active respiratory infections
- Stable other medications for 4+ weeks
Bronchiectasis Research Trials
Advanced infection prevention and airway protection therapies
Innovative Bronchiectasis Treatments (2025)
Our bronchiectasis research focuses on preventing infections and reducing exacerbations through novel bispecific antibodies and advanced airway protection strategies that target the underlying causes of bronchiectasis progression.
Anti-Pseudomonas Bispecific Antibodies
Revolutionary treatments targeting Pseudomonas aeruginosa infections, designed to prevent exacerbations and reduce antibiotic dependence.
Airway Protection Biologics
Novel therapies aimed at protecting and repairing damaged airways, potentially slowing bronchiectasis progression.
Anti-Neutrophil Elastase Therapy
Targeted treatments to reduce neutrophilic inflammation and prevent further airway damage in bronchiectasis patients.
Mucoregulator Combinations
Advanced combination therapies to improve mucus clearance and reduce bacterial colonization in bronchiectatic airways.
Advantages of Our Bronchiectasis Trials
- Infection Prevention: Reducing the need for rescue antibiotics and hospitalizations
- Exacerbation Reduction: Targeted approaches to prevent bronchiectasis flare-ups
- Quality of Life: Improving daily function and reducing symptoms
- Disease Monitoring: Advanced CT imaging and biomarker assessments
- Antibiotic Sparing: Potentially reducing antibiotic resistance risks
Bronchiectasis Trial Eligibility
Clinical Requirements
- Confirmed bronchiectasis on high-resolution CT
- History of exacerbations requiring antibiotics
- Non-cystic fibrosis bronchiectasis
- Ages 18-85 years
Microbiological Criteria
- Chronic Pseudomonas aeruginosa colonization (some studies)
- Elevated inflammatory markers
- Recurrent bacterial infections
- Specific bronchiectasis severity scores
Why Choose Lung Research Florida
Leading respiratory research with patient-centered care and cutting-edge science
Research Excellence
Dr. Hull's 20+ years of clinical research experience with multiple FDA-approved treatments developed through our trials
Latest 2025 Advances
Access to the most promising treatments 3-5 years before they become available to the general public
Free Medications
All investigational treatments provided at no cost, including advanced biologic therapies worth thousands of dollars
Personalized Medicine
Biomarker-driven treatment selection to match you with the most effective therapy for your specific condition
Comprehensive Care
Complete medical monitoring with advanced diagnostics and expert pulmonary care throughout your trial participation
Hope for Remission
Focus on achieving clinical remission and long-term disease modification, not just symptom management
Ready to Explore Clinical Trial Options?
Take the first step toward accessing cutting-edge treatments for your respiratory condition. Our experienced research team will guide you through the process and help determine which trials might be right for you.
Research Referrals: 954-520-7296 x1
General Inquiries: